PharmaDeals Corp-METRx 5 year data analysis recognises that investment in deal making activity is a long term activity with payoff often many years in the future. A deal struck 4 years ago for a development stage asset may be highly relevant to the patent risk a corporation currently faces in that same indication. It is also pertinent to consider more recent activity when considering the immediate competitive challenges the major players currently face. The new 12 month section in Corp-METRx does just that.